Strategic Mutations in Designer Native Peptides Combat NLRP3 Inflammasome Activation in Neurodegenerative Disorders
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02158 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Sabyasachi Mandal und 2 weiteren Autor:innen. Beteiligte Einrichtung: Bioorganic Chemistry Laboratory, New Chemistry Unit, Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Jakkur P.O., Bengaluru 560064…. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes, Neurodegenerative Diseases, Mutation. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Council of Scientific and Industrial Research, India, Science and Engineering Research Board, Department of Science and Technology, Ministry of Science and Technology, India.
Abstract (Originalsprache)
Nucleotide-binding oligomerization domain (NOD)-, leucine-rich repeat (LRR)-, and pyrin domain (PYD)-containing protein 3 (NLRP3) form an inflammasome by assembling with apoptosis-associated speck-like protein containing a CARD (ASC) and procaspase-1 that plays a pivotal role in various neurodegenerative diseases such as Alzheimer’s and Parkinson diseases. We designed native peptides derived from the PYDs of NLRP3 and ASC based on their interfacial interaction to inhibit NLRP3 inflammasome formation. Screening revealed that NP3, derived from NLRP3, inhibits inflammasome activation. Furthermore, a strategic mutation (F → L) in native peptide NP3 results in MNP2 that selectively binds to PYD of ASC with nanomolar affinity, inhibiting NLRP3 inflammasome formation, interleukin-1β (IL-1β) release, and caspase-1 maturation. MNP2 also reduced potassium (K) and chloride (Cl) ion efflux, key signals in NLRP3 activation, and prevented mitochondrial damage and reactive oxygen species (ROS) production. MNP2 significantly reduced NLRP3 inflammasome formation in neurodegenerative conditions triggered by amyloid-β (Aβ), Tau, and α-Synuclein (α-Syn), suggesting a promising therapeutic strategy for NLRP3-related inflammatory diseases, including neurodegenerative disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Bioorganic Chemistry Laboratory, New Chemistry Unit, Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Jakkur P.O., Bengaluru 560064, Karnataka, India.
ORCID-Profile: Sabyasachi Mandal, Thimmaiah Govindaraju
Förderung
- Council of Scientific and Industrial Research, India
- Science and Engineering Research Board
- Department of Science and Technology, Ministry of Science and Technology, India
- Jawaharlal Nehru Centre for Advanced Scientific Research
Zitieren
APA
Mandal, S., Ramesh, M., & Govindaraju, T. (2025). Strategic Mutations in Designer Native Peptides Combat NLRP3 Inflammasome Activation in Neurodegenerative Disorders. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02158
Vancouver
Mandal S, Ramesh M, Govindaraju T. Strategic Mutations in Designer Native Peptides Combat NLRP3 Inflammasome Activation in Neurodegenerative Disorders. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02158
BibTeX
@article{Mandal2025,
author = {Mandal, Sabyasachi and Ramesh, Madhu and Govindaraju, Thimmaiah},
title = {Strategic Mutations in Designer Native Peptides Combat NLRP3 Inflammasome Activation in Neurodegenerative Disorders},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02158}
}
EUVIMED